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ABSTRACT
Background: The inflammatory milieu in the liver as determined by histopathology is different in
individual patients undergoing autologous islet cell transplantation. We hypothesized that
inflammation related to fatty-liver adversely impacts islet survival. To test this hypothesis, we used a
mouse model of fatty-liver to determine the outcome of syngeneic islet transplantation after chemical
pancreatectomy. Methods: Mice (C57BL/6) were fed a high-fat-diet from 6 weeks of age until attaining
a weight of 28 grams (6–8 weeks) to produce a fatty liver (histologically > 30% fat);steatosis was
confirmed with lipidomic profile of liver tissue. Islets were infused via the intra-portal route in fatty-
liver and control mice after streptozotocin induction of diabetes. Outcomes were assessed by the rate
of euglycemia, liver histopathology, evaluation of liver inflammation by measuring tissue cytokines IL-
1b and TNF-a by RT-PCR and CD31 expression by immunohistochemistry. Results: The difference in
the euglycemic fraction between the normal liver group (90%, 9/10) and the fatty-liver group (37.5%,
3/8) was statistically significant at the 18th day post- transplant and was maintained to the end of the
study (day 28) (p D 0.019, X2 D 5.51). Levels of TNF–a and IL-1b were elevated in fatty-liver mice (p D
0.042, p D 0.037). Compared to controls cytokine levels were elevated after islet cell transplantation
and in transplanted fatty-liver mice as compared to either fatty- or islet transplant group alone (p D
NS). A difference in the histochemical pattern of CD31 could not be determined. Conclusion: Fatty-
liver creates an inflammatory state which adversely affects the outcome of autologous islet cell
transplantation.
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Introduction
The liver has been the site of choice for islet trans-
plantation in clinical practice. In recent years it has
become increasingly recognized that intra-portal
infusion of isolated islet cells may not provide the
ideal microenvironment for islets due to various fac-
tors that contribute to the loss of islet mass early after
infusion.1 Many crucial events occurring in the hours
and days after islet infusion influence the success of
transplantation. During islet infusion an instant
blood-mediated inflammatory reaction (IBMIR) is
elicited when islets are exposed to blood and involves
the coagulation cascade including complement acti-
vation.2, 3 The inflammatory process is triggered by
tissue factors secreted by endocrine cells, which leads
to the generation of thrombin. Thrombin-activated
platelets bind to the islet surface and then the ampli-
fication loop involving factor XI and activated plate-
lets generate a fibrin capsule surrounding the islets.4-
6 Intra-portal islet infusion is also associated with
thrombosis and hepatic tissue ischemia caused by
islet entrapment in liver sinusoids that leads to
sinusoidal endothelial cell activation and functional
impairment.7 Finally, the IBMIR culminates in the
disruption of islet morphology by infiltrating
leukocytes. Polymorphonuclear cells (PMNs) are the
predominant cell type infiltrating the islets, attracted
by the upregulation and release of ischemia-induced
molecules (i.e., tissue factor, IL-1beta, tumor necrosis
factor-alpha (TNF-alpha), nitric oxide, high-mobility
group box 1 (HMGB1)) and by proinflammatory
signals (i.e., monocyte chemoattractant protein
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(MCP-1), IL-8, IL-6) released from the islet.8-10 After
activation, PMNs secrete reactive oxygen species that
are short-lived and lead to rapid and direct damage
of the islets.11
Revascularization of transplanted islets is crucial for
glucose homeostasis, not only because beta cells have a
high oxygen consumption rate, but also because of the
need for timely response to changes in plasma glucose
concentration and nutrient-dependent hormone
release directly into the blood.12 Intra-liver islet revas-
cularization is a well-described process in which endo-
thelial cells form intra-islet blood vessels in the first 3
to 5 days post-transplant and full blood circulation is
re-established within approximately 10 to 14 days.13-18
In autologous islet cell transplant (AIT) after total
pancreatectomy (TP) and infusion of islet cells into
the liver via the portal vein, emphasis has been placed
on selection of cases, prediction of islet yield, surgery,
islet isolation and degree of pancreatic damage and
fibrosis.19, 20 The livers of patients with chronic pan-
creatitis are less scrutinized and may not be normal.
For example, many with alcoholic chronic pancreatitis
have varying degree of fat or fibrosis in the liver;
patients with autoimmune pancreatitis have some
peri-portal inflammation. Most of the literature
regarding islet engraftment biology does not empha-
size the histopathological variation of the liver, nor
the reaction to islet implantation. In a prior clinical
observation we described three subsets of patients
based on their liver histopathology.21 We noted that
transaminitis following islet cell infusion, was signifi-
cantly greater in the fatty-liver group. Characterized
by transaminitis inflammation is a known feature of
fatty-liver and provides an unstable environment for
islet infusion. Steatosis in addition to the IBMIR may
produce an exaggerated inflammatory response result-
ing in an adverse effect on engraftment and vasculari-
zation of islets. Histologic evaluation of the liver is not
always done pre-AIT and the intrahepatic factors that
could influence the successful outcome of islets infu-
sion are not well defined. Factors influencing the suc-
cess of AIT include the uniformity of the islet yield,
isolation factors, and liver pathology. The aim of this
study is to evaluate the effect of hepatic steatosis on
AIT and the role of inflammation on euglycemia.
Since its almost impossible to obtain uniformity in a
clinical setting we developed animal experiment to
study the effect of having a fatty-liver while keeping
other factors uniform.
Results
Establishment of the fatty-liver mouse model
Twenty, 6-week-old, mice fed a high-fat-diet for
6–8 weeks were harvested when their body weights
had exceeded 28 grams, and their IPGTT was nor-
mal and fat content of the liver was confirmed
(Fig. 1). Eight mice satisfied the criteria, weight
range 31–37 grams, histologically liver having at
least 25–30% (confirmed at 28 days). Based on this
criteria, we used other set of 20 mice and per-
formed the experiment. However, only eight of
these mice satisfied the liver fat content criteria
upon sacrificed and hence those were used for the
analysis.
Figure 1. Establishment of mouse fatty liver model. (A) Glu-
cose solution (2g/kg) was injected into the mouse peritoneal
cavity after 12 hours of fasting. The blood samples were
taken from the tail vein at 0, 10, 30, 60, and 120th minutes
after glucose injection. Blood glucose levels were assessed
with a Bayor glucometer. (B) Body weight of fatty liver mice.
(C) A representative image of H&E stain on the harvested
mouse liver.
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Glycemic conversion after Islet transplantation
In the normal liver (control) group (Fig. 2 A), 7 out of
10 recipient mice became euglycemic on the first day
after the islet transplantation, and 4 out of the 7 mice
sustained euglycemia until the termination of this
experiment at 28 days after transplantation. Overall, 9
of 10 mice restored normal blood glucose from day 1
to day 18 post-transplantation. In contrast to the con-
trol group, 7 out of 8 recipient mice in the fatty-liver
group (Fig. 2 B) achieved normal blood glucose levels
on the first day. Only 2 of the 7 mice remained eugly-
cemic until 28 days after islet transplantation. Four of
7 mice lost graft function within one week after a short
period of restoration of normal blood glucose. One
recipient mouse became euglycemic 4 days after
transplantation and remained euglycemic til the end
of the study. The euglycemic fraction was therefore
decreased from 87.5% (7/8) on the first day to 37.5%
(3/8) on the 7th day after transplantation in the fatty-
liver group, while it was 70% (7/10) on the first day,
dropping to 40% (4/10) on the second day, and
increasing gradually to 90% (9/10) by the 18th day of
transplantation in the normal liver (Fig. 2 C). The dif-
ference in the euglycemic fraction between the normal
liver group (90%, 9/10) and the fatty-liver group
37.5%, 3/8) was statistically significant at the 18th day
post-transplantation and maintained to the end of this
study (day 28) (p D 0.019, X2: 5.51).
On the H&E examination of livers harvested from
mice at 28 days (Fig. 3), graft islets were observed in
the recipient livers of both groups. In addition, hepatic
steatosis was confirmed in the study group from the
mice receiving the high-fat-diet, while the livers from
mice in the control group were histologically normal
in structure. Immunohistological (CD31) staining
demonstrated engrafted islets in recipient livers of
both groups (Fig. 4), similarly to the H&E staining
Figure 2. Blood glucose profile after syngeneic islet transplantation. The recipient mice were rendered diabetic by streptozotocin
(200 mg/kg IP). Diabetic animals from both normal liver control group and the fatty liver group were received 500 islets by intra-portal
injection. Serial blood glucose levels were measured. The non-fasting blood glucose results from the normal liver control group and the
fatty liver group shown in (A) and (B) respectively. (C) Summary of the euglycemic fraction. The conversion to euglycemia was defined
as glucose levels < 200 mg/dL for > 2 consecutive days.
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Figure 3. H&E stained mouse islets in the mouse livers after intra-portal transplantation. The livers from the recipient mice in
both groups were harvested at 28 days after islet transplantation. The liver samples were fixed in 10% formalin, and embedded
in paraffin. Five consecutive liver sections with 5-micron thickness were collected at every 100um intervals. One of 5 sections
was subjected to H&E staining.
Figure 4. Immunohistochemistry stain with CD31 on mouse islets in the mouse liver after intra-portal transplantation. The liver section
from the five consecutive sections described previous in the H&E stain on the harvested liver 28 days after islet transplantation.
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result (Fig. 3). However, quantitative analysis was not
possible.
TNF-a and IL-1b assessment with real time RT-PCR
The expression of proinflammatory cytokines, TNF-a
and IL-1b, was increased by over 50% in the fatty-liver
group and the fatty-liver group after islet transplanta-
tion compared to the normal liver control group.
TNF–a mRNA expression in the normal liver group
demonstrated only a 1.25 § 0.363 fold increase com-
pared to baseline, whereas the TNF–a mRNA expres-
sion was 2.7 § 0.499 (p D 0.02) in the fatty-liver
group, and 6.68 § 3.0 (p D 0.04) in the fatty-liver
with islet transplant group, respectively. Similarly in
the control group IL-1b mRNA expression only
exhibited a modest increase of 1.254 § 0.348 com-
pared to a, 3.781 § 0.885 (p D 0.037) level in the
fatty-liver group, and 5.47 § 1.39 (p D 0.0428) in the
fatty-liver with the islet transplant group (Fig. 5).
Lipodomics study
Unsupervised principle component analysis (PCA)
plots of the lipid signature showed that the hepatic lip-
idome of normal liver control mice was segregated
from that of fatty-liver mice. PCA also showed clear
separation by islet transplantation (Fig. 6A).
Statistical analysis was performed to identify the lip-
ids with statistically significant difference in liver from
control mice compared to fatty-liver mice. The volcano
plot (Fig. 6B) shows the log10 FDR corrected p-value
(y-axis) vs. log2 fold change (fatty-liver/control) for
each detected ion. The dots above 1.0 on y-axis are ions
with p-values < 0.1 by Welch’s T-test. Relative levels of
representative ions, two diadylglycerols and one triadyl-
glycerol are shown in Fig. 6C. Levels of these three glyc-
erolipids increased significantly in liver from fatty-liver
mice compared to that from control mice (p < 0.05).
Putative molecules were designated by screening the
accurate mass in metabolite databases, including
HMDB, KEGG, LIPIDMAPS, and BioCyc databses.
KEGG pathway analysis results indicated the metabolic
pathways associated with the differential ions.
Discussion
The purpose of this study was to investigate the role of
fatty liver in autologous islet transplantation. We have
previously shown that hepatic steatosis is common in
patients with chronic pancreatitis.21 In this current
investigation we demonstrated that diet-induced
hepatic steatosis creates a inflammatory microenviron-
ment that is hostile to islet cells and adversely alters
their successful transplantation. We confirmed steatosis
histologically and showed that the expression of pro-
inflammatory cytokines directly correlated to successful
AIT and post-transplantation euglycemic control.
The need for an immune competent animal model
for this study and its’ uniqueness is easily understood
given that in the clinical setting factors such as pancre-
atic pathology, variations in surgical technique, warm
ischemia time and the varying degrees of islet yield in
different patients make it difficult to estimate the iso-
lated effect of steatosis on the outcome of TP-AIT.
Inflammation related to IBMIR has been studied in
a mouse islet model before. In a study by Wang et al.
Figure 5. Local inflammatory responses after intra-portal islet transplantation. Five hundred mouse islets were transplanted in both nor-
mal liver and the fatty liver groups. Livers were harvested 24 hours after transplantation. mRNA expression of TNF-a and IL-b was quan-
tified by real time RT-PCR. Data are presented as mean § standard error, p < 0.05.
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there was a significant improvement in islet graft sur-
vival after intraportal islet transplantation by using
alpha-1-antitrypsin.22 The authors maintained that
this improvement was by virtue of the mitigation of
coagulation in IBMIR and suppression of cytokine-
induced JNK and NF-kB activation. As noted by Citro
et al. it is not clear which of the many pathways that
can result in inflammation are involved in either islet
isolation or intraportal islet transplantation.23 In a
large part we would argue that these authors and
others are underplaying the pre transplant host envi-
ronment and as we have demonstrated this may be as
big a factor as the process of infusion.
Our results show very different euglycemic conver-
sion patterns in the fatty-liver versus control mice
after islet transplantation. Fatty-liver mice became
euglycemic immediately after islet transplantation but
could not sustain good glycemic control at 18 days.
The control mice with normal livers had a immediate
euglycemic rate that was less impressive, but good glu-
cose control was subsequently maintained. We postu-
late that this is because in fatty-livers with increased
inflammation (which we have demonstrated by
increased baseline TNF-a and IL-1b in fatty-livers
compared to normal livers), there is greater destruc-
tion of islet cells in the early phase and the insulin that
is liberated gives the appearance of good glucose con-
trol only to fade as the islet cells die off. In normal liv-
ers, the islet cell destruction is limited due to less
inflammation and since not many cells are destroyed
the euglycemic peak is less impressive as compared to
the fatty-livers. However with more cells surviving
engraftment, glycemic control continues to improve
and is sustained. Though not performed at the time,
tracking of C-peptide may further support this
hypothesis. Elevated levels of TNF-a and IL-1b were
noticed in fatty-liver mice more so after islet infusion
than in normal liver but the change was not
Figure 6. Statistical analysis of liver lipidomics profiling results from mice fed normal diet and high fat diet. (A) Multivariate analysis of
lipidomic profiles from normal diet- and high fat-fed mice with or without islet transplantation. Principle components analysis (PCA)
unsupervised clustering plots for both positive and negative mode data are shown. (B) Volcano plot displays significant differential ions.
Ions labeled above 1.0 on y-axis have significant difference in intensity between high fat-fed mice and normal diet-fed ones. (C) Relative
levels of diglyceride and triglyceride ions in high fat-fed and normal diet-fed groups.
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statistically significant. Of note, there are many other
inflammatory cytokines/chemokines that could have
been tested, but considering the limitation of funding
in such a pilot experiment, we selected the most com-
mon and representative markers. We tried looking
into the engraftment process by CD31 staining but
possibly because of sampling limitations we could not
appreciate a difference.
Limitations of this study include the small number
of mice used for the experiment because it is a pilot
study. One of the main challenges was to produce
euglycemic fatty-liver mice, i.e., with a normal IPGTT.
As mentioned in the methods, we had to sacrifice a
considerable number of mice to get the cohort which
would satisfy the experimental selection criteria
decreasing the number in the actual experiment. It
can also be argued that macrosteatosis observed in
this study may be little higher than that observed in
the clinical setting of islet autotransplantation. Our
previous clinical observation does support the notion
that many patients have significant fat and fibrosis in
their liver .21 It can be also be argued that the diet
induced obesity model may not be directly relevant in
the clinical setting. This model however provided a
histopathologically uniform group that cannot be oth-
erwise reproduced in the clinical setting.We would
also concede that portal vein pressure should be mea-
sured during the islet infusion, but as shown in our
earlier clinical study the liver histopathology has no
effect on change in portal pressure from pre- to post-
infusion.21
In conclusion, the variation in liver histopathology,
in particular steatosis, has a significant adverse effect
on achieving sustainable euglycemia after autologous
islet transplantation. We aim to direct our efforts
towards a more elaborate study with greater differenti-
ation. The clinical application of this study could be
appreciated in developing future prospects like patient
selection, working on reducing fat content of liver
before surgery, pretreatment of fatty liver rather
than just generally reducing inflammation with anti-
inflammatory drugs.
Materials and methods
Animal model for hepatic steatosis
We compared the outcomes of islet cell transplanta-
tion in non-diabetic fatty-liver mice to normal
control mice. The mice were rendered chemically
diabetic and subjected to syngeneic islet transplanta-
tion in this model; male C57BL/6J (B6) mice (5 and
10 weeks old, Charles River Laboratories, MD) were
used as islet recipients and donors, respectively. All
mouse studies were performed in an ethical fashion
and approved by the IACUC committee for animal
research by the Georgetown University Comparative
Medicine Department.
To create the fatty-liver mice, B6 mice (5-week old)
were fed a high-fat-diet with free access to water. The
rodent diet high in fat (58Y1, blue) was purchased from
TestDiet (St. Louis, MO). This diet was composed of
34.9% fat and with this diet animals obtained 60% of
their energy in kilocalories from fat. The fat composi-
tion consisted of 13.68% total saturated fatty acids and
14% total monounsaturated fatty acids. The diet was
stored in dry refrigerated conditions at 4C. The control
mice received a regular fat diet (#5001) also from Test-
Diet (St. Louis, MO) with similar but less kilocalories
(5 kcal/gm vs 4.1 kcal/gm). This diet contained 6.45%
fat with 1.48% total saturated fatty acids and 1.62% total
monosaturated fatty acids. Body weight and non-fasting
blood glucose (NFBG) of the mice were monitored
weekly. Part of the group of mice achieving a body
weight 28g and normal NFBG, <200mg/dl) were sac-
rificed and their livers were harvested for histologic
examination using Hemotoxylin and Eosin (H&E) stain
to assess liver fat content.
Induction of diabetes with streptozotocin
Fatty-liver and control B6 mice were made chemically
diabetic by intraperitoneal (IP) injection of 200 mg/kg
streptozotocin in citrate buffered saline and screened
for the development of diabetes. All mice underwent
intraperitoneal glucose tolerance test (IPGTT); after
12 hours of fasting, glucose solution, 2g/kg body
weight was injected into the mouse peritoneal cavity
with a 1ml syringe. Then blood was sampled (one
drop) from the tail vein at 0, 10, 30, 60, and 120th
minutes. The blood samples were immediately tested
for blood glucose using a Bayer glucometer.
Mice whose NFBG was> 250 mg/dL on two conse-
cutive measurements were considered diabetic.
Harvesting of islets and autologous islet
transplantation
Donor B6 mouse pancreata were removed after disten-
sion with collagenase RL (1 mg/ml, Roche, Indianapolis,
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IN) through the common bile duct. Following digestion,
islets were purified by a Ficoll discontinuous gradient
(1.108, 1.096, and 1.037; Mediatech Inc, Herndon, VA).
Isolated islets were cultured for 24 hours in RPMI 1640
supplemented by 10% FCS, L-glutamine (2 mM), and
penicillin (100 U/mL), streptomycin (100 mg/mL)
and amphotericin B (0.25 mg/mL) (Mediatech Inc,
Herndon, VA). Viability was evaluated using a Live/
Dead Cell Viability/Cytotoxicity Kit (Molecular Probes,
Inc., Eugene, OR) and only isolations with > 90%
viability were used for transplantation.
Diabetic fatty-liver and control B6 mice underwent
intra-portal islet transplantation under 1% Isoflurane
for anesthesia. In brief, 500 hand-picked B6 islets were
infused in a total volume of 200 mL into the recipient
liver through the portal vein using a 27 Ga insulin
syringe, as previously described.24
Mice undergoing islet transplantation were moni-
tored by measuring NFBG daily for two weeks with a
Bayer glucometer. Euglycemia was defined as NFBG
< 200 mg/dL on two consecutive days.
Evaluation of livers histologically and for
inflammation
Livers were harvested 28 days after intraportal islet
transplantation from both groups, fixed in 10%
formalin, and embedded in paraffin. Five-micron step-
sections at 100 mm intervals were obtained. Five con-
secutive sections were collected from each step section
for histological examination; Hematoxylin & Eosin
(H&E)and immunohistochemistry.
Immunohistochemical staining of the harvested
mouse liver tissue sections was performed with CD31/
PECAM (Novus Biological, CO, USA). Five micron
sections from formalin fixed paraffin embedded tissues
were de-paraffinized with xylene and rehydrated
through a graded alcohol series. Heat induced epitope
retrieval (HIER) was performed by immersing the tis-
sue sections at room temperature for 20 minutes in
Proteinase K. Immunohistochemical staining was per-
formed using a horseradish peroxidase labeled polymer
from Vector MP-7444 according to manufacturer’s
instructions. Briefly, slides were treated with 3% hydro-
gen peroxide and 2.5% normal goat serum (from Kit)
for 20 minutes each, and exposed to primary antibodies
for CD31/PECAM, Novus Biological, NBP2-11848
(1:75) overnight at 4C. Slides were exposed to the
ImmPRESS Anti-Rat Ig (mouse adsorbed) labeled
polymer for 30 minutes and DAB chromagen (Dako)
for 5 minutes. Slides were counterstained with Hema-
toxylin (Fisher, Harris Modified Hematoxylin) at a 1:9
dilution for 2 minutes at RT, blued in 1% ammonium
hydroxide for 1 minute at room temperature,
dehydrated, and mounted with Acrymount. Sections
with omitted primary antibody were used as negative
controls.
Hepatic cytokine expression by real-time RT-PCR
Liver samples were harvested 24 hours after islet trans-
plantation and subjected to total RNA extraction to
determine levels of TNF-a and IL-1 mRNA. Total RNA
of liver samples was isolated and purified using RNeasy
Mini Kit (Qiagen, Balencia, CA) according to the man-
ufacturer instructions. Synthesis of complementary
DNA (cDNA) was performed by using 1 ug of total
RNA and High Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientific, Waltham, MA). Quanti-
tative real-time polymerase chain reaction (qPCR) was
performed on StepOne Plus (Applied Biosystems,
Waltham, MA) with TaqMan Gene Expression Master
Mix (Applies Biosystems, Foster City, CA). The
amplification was performed in a 20 ul reaction mixture
containing 10 ul TaqMan Gene Expresion Master Mix,
4 ul cDNA and 1x of each primer for a specific target.
Primers for qPCR were commercially available
from Thermo Fisher Scientific (Mm03928990_g1 for
18S ribosomal RNA, Mm00434228_m1 for IL-1b,
Mm00443258_m1 for TNF-a). The amplification con-
ditions consisted of one denaturation/activation cycle at
95C for 10min, followed by 40 cycles at 95C for 15 s
and 60 C for 60 s. The individual targets for each sam-
ple were quantified by determining the cycle threshold
(Ct) and by comparison with the reference samples.
The relative amount of the target mRNA was normal-
ized with the reference gene 18s rRNA.
Metabolomic/lipidomic profiling
Snap-frozen liver tissues (10 mg) were homogenized
in 300 mL chilled 50% methanol containing trinona-
decenoin (TG (19:1/19:1/19:1), with a final concen-
tration of 500 nM. Chloroform (600 mL) was added
to the homogenates and vortexed for 10 seconds.
HPLC grade water (300 mL)was then added and vor-
texed for 10 seconds. The tissue homogenates were
centrifuged at 13,000 rpm for 15 minutes at 4C. The
upper aqueous phase and bottom organic layer were
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collected into silica tubes. Supernatants were air
dried by speed vacuum. The residues were reconsti-
tuted in 100 mL of 50% methanol for analysis. All
chemicals were of LC-MS grade and obtained from
Sigma-Aldrich (St. Louis, MO).
Acquity CSH C18 50 £ 2.1 mm 1.7-mm column
(Waters Corp, Milford, MA) was used for lipidomics
profiling by UPLC-QTOFMSE. MSE is a technique by
which both precursor and fragment mass spectra are
acquired by alternating between high and low collision
energy during a single chromatographic run using
chromatographic and mass spectrometric parameters
according to our previous study.25
Raw mass spectrometric data were processed using
MarkerLynx software (Waters Corp, Milford, MA) to
generate a data matrix that consisted of the retention
time, m/z value, and the normalized peak area.
Statistical analysis and putative ion identification on
the post-processed data were conducted utilizing
MetaboLyzer.26 Lipid ions were validated with the
fragmentation provided in MSE results. Metabolic
pathway information from KEGG as well as BioCyc
was further utilized for creating pathway hit histo-
grams and enrichment significance graphs.
Statistical analysis
All data are expressed as mean § standard deviation.
Comparison between groups was performed by a Stu-
dent’s t test. Statistical significance was established at
p < 0.05. Analysis of eugylcemic conversion over time
was performed by Kaplan-Meier method with a Log-
rank test to assess statistical significance (Prism Soft-
ware, GraphPad, Inc.).
Abbreviations page
C Celcisus degree
cDNA complementary deoxyribonucleic
acid
dL deciliter
DNA deoxyribonucleic acid
FCS Fetal calf serum
g gram
Ga gauge
HPLC high performance liquid
chromatography
IACUC Institutional Animal Care and Use
Committee
IL-1 Interleukin-1
KEGG Kyoto encyclopedia of genes and
genomes
Kg Kilogram
LC-MS Liquid chromatography-mass
spectrometry
mg milligram
mL milliliter
mM millimole
mRNA Messenger ribonucleic acid
qPCR Quantitative polymerase chain
reaction
RNA Ribonucleic acid
U unit
ug microgram
uL microliter
um micrometer
UPLC-QTOFMS Ultra performance liquid chroma-
tography-quadrupole time of flight
mass spectrometry
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